These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25466728)

  • 1. Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data.
    Candoni A; Aversa F; Busca A; Cesaro S; Girmenia C; Luppi M; Rossi G; Venditti A; Nosari AM; Pagano L
    J Chemother; 2015 Feb; 27(1):1-12. PubMed ID: 25466728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination antifungal therapy: what can and should we expect?
    Johnson MD; Perfect JR
    Bone Marrow Transplant; 2007 Aug; 40(4):297-306. PubMed ID: 17563740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies.
    Maertens J
    Eur J Haematol; 2007 Apr; 78(4):275-82. PubMed ID: 17241370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology and outcomes of patients with invasive mould infections: a retrospective observational study from a single centre (2005-2009).
    Klingspor L; Saaedi B; Ljungman P; Szakos A
    Mycoses; 2015 Aug; 58(8):470-7. PubMed ID: 26152371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014.
    Blyth CC; Gilroy NM; Guy SD; Chambers ST; Cheong EY; Gottlieb T; McGuinness SL; Thursky KA
    Intern Med J; 2014 Dec; 44(12b):1333-49. PubMed ID: 25482744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zygomycosis--current epidemiological aspects.
    Glöckner A; Vehreschild JJ; Cornely OA
    Mycoses; 2007; 50 Suppl 1():50-5. PubMed ID: 17394610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The rationale of combination antifungal therapy in severely immunocompromised patients: empiricism versus evidence-based medicine.
    Chamilos G; Kontoyiannis DP
    Curr Opin Infect Dis; 2006 Aug; 19(4):380-5. PubMed ID: 16804387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posaconazole: an extended-spectrum triazole antifungal agent.
    Schiller DS; Fung HB
    Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combination antifungal therapy in hematopoietic stem cell transplantation patients].
    Jacoby E; Keller N; Barkai G
    Harefuah; 2012 Aug; 151(8):455-7, 499, 498. PubMed ID: 23350288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newer antifungal agents for invasive fungal infections in patients with haematological malignancy.
    Rogers TR; Frost S
    Br J Haematol; 2009 Mar; 144(5):629-41. PubMed ID: 19120371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination antifungal therapy: a critical review of the evidence.
    Ostrosky-Zeichner L
    Clin Microbiol Infect; 2008 May; 14 Suppl 4():65-70. PubMed ID: 18430131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.
    Tacke D; Buchheidt D; Karthaus M; Krause SW; Maschmeyer G; Neumann S; Ostermann H; Penack O; Rieger C; Ruhnke M; Sandherr M; Schweer KE; Ullmann AJ; Cornely OA
    Ann Hematol; 2014 Sep; 93(9):1449-56. PubMed ID: 24951122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?
    Rogers TR; Slavin MA; Donnelly JP
    Br J Haematol; 2011 Jun; 153(6):681-97. PubMed ID: 21504422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts.
    Metcalf SC; Dockrell DH
    J Infect; 2007 Oct; 55(4):287-99. PubMed ID: 17697716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invasive pulmonary aspergillosis: comparative analysis in cancer patients with underlying haematologic malignancies versus solid tumours.
    Dib RW; Khalil M; Fares J; Hachem RY; Jiang Y; Dandachi D; Chaftari AM; Raad II
    J Hosp Infect; 2020 Mar; 104(3):358-364. PubMed ID: 31585141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward more effective antifungal therapy: the prospects of combination therapy.
    Kontoyiannis DP; Lewis RE
    Br J Haematol; 2004 Jul; 126(2):165-75. PubMed ID: 15238137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in antifungal chemotherapy.
    Petrikkos G; Skiada A
    Int J Antimicrob Agents; 2007 Aug; 30(2):108-17. PubMed ID: 17524625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifungal treatment strategies in high risk patients.
    Rüping MJ; Vehreschild JJ; Cornely OA
    Mycoses; 2008 Sep; 51 Suppl 2():46-51. PubMed ID: 18721331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis).
    Lortholary O; Fernández-Ruiz M; Perfect JR
    J Antimicrob Chemother; 2016 Nov; 71(suppl 2):ii31-ii36. PubMed ID: 27880667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in antifungal prevention and treatment.
    Groll AH; Tragiannidis A
    Semin Hematol; 2009 Jul; 46(3):212-29. PubMed ID: 19549575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.